Acarix A/S was established in 2009 as a spinout from Coloplast A/S. Since 2010, key investors SEED Capital Denmark and Sunstone Life Science Ventures have financed the company and supported it towards market introduction. Acarix is a medical device company specializing in non-invasive, non-radiation acoustic detection of Coronary Artery Disease (CAD).
The CADScor®System combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient specific CAD-score in less than 10 minutes. The CADScor®System meets a major unmet need as Coronary Artery Disease (CAD) affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to expensive and potentially harmful imaging and invasive coronary angiography, is inefficient.
A recent Danish study showed that more than 90% of patients presenting Coronary Artery Disease (CAD) symptoms to their general practitioner do not have CAD. With the Acarix CADScor®System we have an easy to use non-invasive tool able to rule out CAD with 96% negative predictive value. This also translates into a potential to reduce onward patient referrals by ~50%. – a win-win for patients, payers and physicians.